Trial · NCT07909031
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Dose Escalation - incidence and nature of dose-limiting toxicities | From the first dose of study drug up until approximately 1 month | Per cohort |
| Primary | Part 1: Dose Escalation - characterization of the maximum tolerated dose, if applicable | From the first dose of study drug up until approximately 1 month | Per cohort |
| Primary | All Parts - incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events | From the first dose of study drug until 90 days after the last dose of study drug | Events are graded according to National Cancer Institute Cancer Terminology Criteria for Adverse Events (NCI CTCAE) |
| Primary | All Parts - incidence and severity of TEAEs leading to dose modifications | From the first dose of study drug until 90 days after the last dose of study drug | |
| Primary | All Parts - incidence and severity of TEAEs leading to treatment discontinuation | From the first dose of study drug until 90 days after the last dose of study drug | |
| Secondary | All Parts - determination of recommended phase 2 dose(s) | From the first dose of study drug until 90 days after the last dose of study drug | |
| Secondary | All Parts - serum CR-002 pharmacokinetic parameters | Predose until up to approximately 36 months | AUC0-inf after a single dose and steady state parameters, as appropriate |
| Secondary | All Parts - serum CR-002 pharmacokinetic parameters | Predose until up to approximately 36 months | AUClast after a single dose and steady state parameters, as appropriate |
| Secondary | All Parts - serum CR-002 pharmacokinetic parameters | Predose until up to approximately 36 months | Cmax after a single dose and steady state parameters, as appropriate |
| Secondary | All Parts - serum CR-002 pharmacokinetic parameters | Predose until up to approximately 36 months | Tmax after a single dose and steady state parameters, as appropriate |
| Secondary | All Parts - serum CR-002 pharmacokinetic parameters | Predose until up to approximately 36 months | Vd after a single dose and steady state parameters, as appropriate |
| Secondary | All Parts - serum CR-002 pharmacokinetic parameters | Predose until up to approximately 36 months | CL after a single dose and steady state parameters, as appropriate |
| Secondary | All Parts - serum CR-002 pharmacokinetic parameters | Predose until up to approximately 36 months | t½ after a single dose and steady state parameters, as appropriate |
| Secondary | All Parts - incidence of participants with detectable antidrug antibodies | Predose until up to approximately 36 months | |
| Secondary | All Parts - overall response rate (ORR) | Predose until up to approximately 36 months | |
| Secondary | All Parts - duration of response (DOR) | Predose until up to approximately 36 months | |
| Secondary | All Parts - disease control rate (DCR) | Predose until up to approximately 36 months | |
| Secondary | All Parts - clinical benefit rate (CBR) | Predose until up to approximately 36 months | |
| Secondary | All Parts - time to response (TTR) | Predose until up to approximately 36 months | |
| Secondary | All Parts - progression free survival (PFS) | Predose until up to approximately 36 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07909031/registered